Drug General Information (ID: DDIHA0GPT1)
Drug Name			Levacetylmethadol		Drug Info		Inotuzumab ozogamicin		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Analgesics				Antineoplastics

Mechanism of Levacetylmethadol-Inotuzumab ozogamicin Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Levacetylmethadol				Inotuzumab ozogamicin
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Levacetylmethadol and Inotuzumab ozogamicin

Recommended Action
Management		Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
3	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".